Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients.
Nonomura Y, Otsuka A, Nakashima C, Seidel JA, Kitoh A, Dainichi T, Nakajima S, Sawada Y, Matsushita S, Aoki M, Takenouchi T, Fujimura T, Hatta N, Koreeda S, Fukushima S, Honda T, Kabashima K.
Nonomura Y, et al. Among authors: kabashima k.
Oncoimmunology. 2016 Oct 18;5(12):e1248327. doi: 10.1080/2162402X.2016.1248327. eCollection 2016.
Oncoimmunology. 2016.
PMID: 28123885
Free PMC article.